Australia markets closed

BNTX Jul 2024 87.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.30000.0000 (0.00%)
As of 02:57PM EDT. Market open.
Full screen
Previous close0.3000
Open0.6000
Bid0.0000
Ask0.0000
Strike87.50
Expiry date2024-07-19
Day's range0.2800 - 0.7500
Contract rangeN/A
Volume22
Open interest733
  • Zacks

    Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

    Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

  • Business Wire

    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

    NEW YORK & MAINZ, Germany, June 27, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the

  • GlobeNewswire

    BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

    Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory reviewProstate cancer is